Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
CONCLUSION: These results support the use of nilotinib 300 mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP with low and intermediate risk.
PMID: 29486663 [PubMed - as supplied by publisher]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
More News: Bilirubin | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Nilotinib | Study | Tasigna | Turkey Health